The company incurred a loss in its most recent quarterly results.

Pfizer's payout ratio is around 90% of earnings, which is high for a dividend stock. It reported strong operational growth of 10% in its most recent quarter. The company continues to focus on cutting ...

Pfizer stock is a deep-value kind of blue chip with a yield of more than 7%. The dividend looks safe — for now. The real question is whether there’s enough growth and innovation in the pipeline as the ...

Pfizer shares are trading in the mid-$20s as investors grapple with a critical question: is this battered pharmaceutical giant destined to remain stuck in neutral, or does its aggressive push into ...

Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition ...

Pfizer (NYSE: PFE) is one of the world's largest pharmaceutical companies. It has a long history of innovation and success. Add in a lofty 6.6% dividend yield, and dividend investors are likely to ...

Yesterday, the Pharma giant Pfizer Inc. (PFE) took the unusual step of not only providing its full-year 2025 revenue and earnings numbers but also providing precise guidance for full-year 2026.